TY  - JOUR
AU  - Barthel, Henryk
AU  - Arbizu, Javier
AU  - Drzezga, Alexander
AU  - Garibotto, Valentina
AU  - Lammertsma, Adriaan A.
AU  - Morbelli, Silvia
TI  - Proven validity and management impact of amyloid imaging in Alzheimer’s disease—repetita juvant
JO  - European journal of nuclear medicine and molecular imaging
VL  - 47
IS  - 8
SN  - 1619-7089
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - FZJ-2021-00059
SP  - 1787 - 1790
PY  - 2020
AB  - The Editorial “Suboptimal Validity of Amyloid Imaging-Based Diagnosis and Management of Alzheimer’s Disease: Why It Is Time to Abandon the Approach” which appeared online ahead of print on October 31, 2019, in the EJNMMI [1] has come to our attention. From our point of view, the topic of amyloid imaging is discussed in a biased and opinionated form in this Editorial. Some facts generally accepted by imaging experts and neuropathologists are questioned or neglected, which may leave the reader with a misleading impression that does not correspond with the current state of knowledge. The EANM Neuroimaging Committee, thus, feels the need to correct this impression in order to allow the reader to differentiate between commonly accepted scientific facts versus individual opinions and matters still unresolved, regarding the topic discussed. For space reasons, we will discuss here only the issues with the greatest risk for misleading interpretation.
LB  - PUB:(DE-HGF)16
C6  - 32130450
UR  - <Go to ISI:>//WOS:000540800000002
DO  - DOI:10.1007/s00259-020-04742-w
UR  - https://juser.fz-juelich.de/record/889134
ER  -